Tofacitinib in the Recalcitrant Cases of Alopecia Areata: A Pilot Study
Abstract: Background: Alopecia areata (AA) is an autoimmune disorder where the immune system attacks hair follicles, causing non-scarring hair loss. It is driven by cytotoxic T lymphocytes and the JAK/STAT signaling pathway, leading to inflammation. JAK inhibitors, including tofacitinib, showed promising results in treating AA by reducing interferon and preventing progression. Aims: To know the efficacy of oral Tofacitinib in the recalcitrant cases of alopecia areata, to know safety profile and side effects of oral Tofacitinib during the study period. Materials and Methods: The study was conducted over a period of 6 months from Sept 2023 to May 2024, in recalcitrant cases of alopecia areata age 10-50 years meeting the inclusion and exclusion criteria attending OPD in tertiary care center . 20 patients were considered. The SALT (Severity of Alopecia Areata) score was utilized to assess disease progression and evaluate the effectiveness of tofacitinib. Results: Most common pattern observed was Patchy alopecia areata. The age group ranged from 10 to 50 years and most common age group was
Keywords: Alopecia areata, Tofacitinib, JAK inhibitors, SALT Score
How to Cite?: Dr. Swathi N., Dr. Mangala H C, Dr. Sugareddy, "Tofacitinib in the Recalcitrant Cases of Alopecia Areata: A Pilot Study", Volume 14 Issue 6, June 2025, International Journal of Science and Research (IJSR), Pages: 716-720, https://www.ijsr.net/getabstract.php?paperid=SR25610072825, DOI: https://dx.doi.org/10.21275/SR25610072825